The rival gets the same clock
Human phase 3 · REDEFINE 4; sponsor results February 23, 2026
What happened when the comparator was tirzepatide?
Subject One brings two stopwatches and proposes starting them on different days. Doctide puts both on the same desk. The visitor begins a victory speech, sees the result sheet, and crosses out the first sentence. The sheet stays.
What changes here
CagriSema did not meet the prespecified primary goal of demonstrating non-inferior weight loss to tirzepatide. [1]
Read the study details & dates
REDEFINE 4 · NCT06131437 · Sponsor topline
Novo reported an open-label phase 3 study of 809 people with obesity and comorbidities. Weekly subcutaneous CagriSema 2.4/2.4 mg was compared directly with tirzepatide 15 mg. Efficacy-estimand weight loss, assuming adherence, was 23.0% versus 25.5%; treatment-regimen estimates were 20.2% versus 23.6%. The primary non-inferiority endpoint was not met. [1]
What this does not establish
Open-label assignment was known to participants and investigators. These are sponsor headline results, not a fully reviewed head-to-head paper. Failure to show non-inferiority is not itself a reported superiority test. The announcement does not supply detailed death or serious-event counts; none are invented.
Original sources
Sources reviewed November 3, 2026. Sponsor material is labeled; event dates are distinct from this editorial date. Trial identifiers identify the studies, not an invitation to enroll.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story